Financial Performance - In 2024, the company achieved a revenue of 64,502.19 million yuan, representing a year-on-year growth of 18.65% [1] - The net profit attributable to shareholders was 12,383.25 million yuan [1] - In Q1 2025, the company reported a revenue of 18,649.04 million yuan, with a year-on-year increase of 27.73% [1] - The net profit for Q1 2025 was 4,057.85 million yuan, reflecting a growth of 32.30% [1] Business Strategy - The company focuses on biomedicine and cell immunotherapy, emphasizing a market-oriented and customer-centric approach [1] - A comprehensive optimization of internal management has been implemented to enhance competitiveness and profitability [1] CGT (Cell and Gene Therapy) Development - The company offers a full range of solutions from drug target discovery to commercial production for cell and gene therapy clients [2] - It has developed a series of recombinant proteins and unique antibodies for CAR-T product development, including a specific antibody targeting CD19 [2] - The company has successfully developed nearly 50 GMP-grade products for CGT applications, ensuring high-quality standards [3] ADC (Antibody-Drug Conjugates) Development - ADCs combine targeted antibodies with potent chemotherapy drugs, minimizing harm to normal cells while maximizing therapeutic effects [4] - The company provides a range of products and services for ADC development, including target proteins and linker enzymes [5] Neuroscience Research - The company focuses on providing high-quality recombinant proteins and neurotrophic factors for brain science research [7] - It has developed products targeting neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as diagnostic proteins [7]